出典: meddic

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/05/02 16:44:33」(JST)

wiki en

[Wiki en表示]


  • Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension.
  • de Jesus Perez VA, Rosenzweig E, Rubin LJ, Poch D, Bajwa A, Park M, Jain M, Bourge RC, Kudelko K, Spiekerkoetter E, Liu J, Hsi A, Zamanian RT.SourceStanford University, Stanford, California. Electronic address:
  • The American journal of cardiology.Am J Cardiol.2012 Nov 15;110(10):1546-50. doi: 10.1016/j.amjcard.2012.07.012. Epub 2012 Jul 30.
  • Pulmonary arterial hypertension (PAH) is a disease characterized by increased pulmonary pressures and chronic right heart failure. Therapies for moderate and severe PAH include subcutaneous (SQ) and intravenous (IV) prostanoids that improve symptoms and quality of life. However, treatment compliance
  • PMID 22853986
  • Experiences with treprostinil in the treatment of pulmonary arterial hypertension.
  • Stream AR, Bull TM.SourceUniversity of Colorado Health Sciences Center, Aurora, CO, USA.
  • Therapeutic advances in respiratory disease.Ther Adv Respir Dis.2012 Oct;6(5):269-76. Epub 2012 Aug 6.
  • Pulmonary arterial hypertension (PAH) is a chronic condition of elevated pulmonary arterial pressures with associated increases in pulmonary vascular resistance leading to right ventricular failure, which was almost uniformly fatal prior to the introduction of pulmonary hypertension specific therapy
  • PMID 22868690


  • トレプロスチニル(トレプロスト<sup>®</sup>注射液)の薬理学的特徴および臨床試験成績
  • 小児期肺動脈性高血圧の正しく的確な治療戦略
  • Pathological function of Ca<sup>2+</sup>-sensing receptor in pulmonary arterial hypertension


Remodulin® is a continuous pump therapy available for treating pulmonary arterial hypertension (PAH). Find out if Remodulin is right for you. ... Important Safety Information for Remodulin Continuous intravenous (IV) infusions of ...
The clearance of treprostinil is decreased up to 80% in patients with hepatic insufficiency, requiring therefore cautious dosing in patients with PAH associated with liver disease. There are no studies on the pharmacokinetics of ...